Metavia INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
MTVA
Metavia INCMetaVia Inc. reported positive clinical trial results for its MASH and obesity drug candidates, vanoglipel (DA-1241) and DA-1726, but faces substantial doubt about its ability to continue as a going concern due to recurring net losses and a need for additional capital.
NASDAQ
MTVA
Metavia INC10-K: MetaVia Inc. Navigates Cardiometabolic Focus with Positive Clinical Data and Strategic Realignment
MetaVia Inc. announces positive clinical trial results for its MASH and obesity programs, alongside a strategic realignment and corporate name change.
NASDAQ
MTVA
Metavia INCNeuroBo Pharmaceuticals, a clinical-stage biotech company, released its 2023 annual report, highlighting progress in its cardiometabolic drug development programs and ongoing financial challenges.